Researchers examine the evolutionary race between SARS-CoV-2 and human defenses

Analysis indicated the number of mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) doubles every 72 days.

As the coronavirus disease 2019 (COVID-19) pandemic continues infecting more people, SARS-CoV-2 is also evolving. Several new variants of the virus have now been discovered, some more infectious than the original strains. This suggests that the virus is already in an evolutionary race with its human hosts.

In a study published on the bioRxiv* preprint server, researchers have analyzed this evolution of the virus based on evolutionary ecology theory. Using the virus genomes available in the Global Initiative on Sharing Avian Influenza Data (GISAID) database, the researchers focused their inquiry on mutations in the receptor-binding domain (RBD) on the spike protein of SARS-CoV-2.

Study: Rapid Evolution of SARS-CoV-2 Challenges Human Defenses. Image Credit: Imilian / Shutterstock
Study: Rapid Evolution of SARS-CoV-2 Challenges Human Defenses. Image Credit: Imilian / Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

The team used their COVID-19 virus Mutation Tracking System, which tracks all mutations in a genome isolate. Using Monte Carlo simulations, they estimated the number of mutations per infected human

The total number of virus copies in the globe is a factor of the number of people infected and the number of copies produced per infected person. But, since testing does not uncover all the true infected cases, the researchers used a model that uses reported COVID-19 deaths to estimate the true number of worldwide infections. The model estimates by March 1, 2021, the number of infections is more than 384 million. Using this, they estimated about 1017 to 1021 copies of the virus were produced worldwide.

Analyzing RBD mutations

The number of RBD mutations increases with the number of virus copies produced, as every time there is transcription of the genome, there is a chance of mutations occurring. Analyzing the RBD variants detected so far, the team estimates a doubling time of the mutants to be about 72 days.

The RBD variants also have mutations in other parts of the viral genome, which leads to about 90,744 unique variants with at least one mutation in the RBD. However, the total number of SARS-CoV-2 variants is much higher as there are mutations also in regions other than the RBD.

Modeling suggested the detected RBD mutations are about 85% of the total variants, which may not be very accurate as it is based on the samples isolated, which could have a bias. Based on the model, it appears that one new mutation occurs for every 600,000 human infections.

Using an estimated 2 million daily infections as of February 15, 2021, this gives about three new effective variants produced every day.

Some of these variants, identified several months ago, are now being seen in the population in larger numbers. One of these successful variants is the B.1.1.7 strain. Here, a specific mutated amino acid seems to appear independently several times. This variant has diverged more and faster than others in the RBD region. In the evolutionary tree, the branch with this variant has led to heavy branches, with one of them diversifying quickly in the last months. In addition, the B.1.351 and P.1 variants are also being selected in the virus evolutionary tree.

Strong selection in SARS-CoV-2 mutations

Although the role of changes to biodiversity affecting the transmission of pathogens from animals to humans has been discussed, less attention has been paid to how a large globally connected human population is accelerating the evolution of SARS-CoV-2. With the number of unique RBD mutations doubling every 72 days, this speed risks outpacing human defenses.

Although the same variations could arise in independent locations, the SARS-CoV-2 evolutionary process is not random, and there is strong selection. These selection processes remove less infectious branches, and branches with more infectious strains become heavier. This is evidenced by the new strains B.1.1.7, B.1.351, and P.1, which appear to be more infectious than the original strain.

The presence of a huge number of available human hosts also allows for another mechanism of virus diversification, reassortment. This process involves an exchange of genetic segments among different virus segments that have infected the same cell, contributing to rapid diversification.

The analysis predicts more infective strains becoming dominant, accelerating the evolutionary rate of the virus, and challenging our ability to contain the pandemic. According to the Red Queen theory, we need to run faster just to keep pace with the virus, and even faster if we have to overcome it.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • Apr 7 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Lakshmi Supriya

Written by

Lakshmi Supriya

Lakshmi Supriya got her BSc in Industrial Chemistry from IIT Kharagpur (India) and a Ph.D. in Polymer Science and Engineering from Virginia Tech (USA).

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Supriya, Lakshmi. (2023, April 07). Researchers examine the evolutionary race between SARS-CoV-2 and human defenses. News-Medical. Retrieved on October 04, 2024 from https://www.news-medical.net/news/20210330/Researchers-examine-the-evolutionary-race-between-SARS-CoV-2-and-human-defenses.aspx.

  • MLA

    Supriya, Lakshmi. "Researchers examine the evolutionary race between SARS-CoV-2 and human defenses". News-Medical. 04 October 2024. <https://www.news-medical.net/news/20210330/Researchers-examine-the-evolutionary-race-between-SARS-CoV-2-and-human-defenses.aspx>.

  • Chicago

    Supriya, Lakshmi. "Researchers examine the evolutionary race between SARS-CoV-2 and human defenses". News-Medical. https://www.news-medical.net/news/20210330/Researchers-examine-the-evolutionary-race-between-SARS-CoV-2-and-human-defenses.aspx. (accessed October 04, 2024).

  • Harvard

    Supriya, Lakshmi. 2023. Researchers examine the evolutionary race between SARS-CoV-2 and human defenses. News-Medical, viewed 04 October 2024, https://www.news-medical.net/news/20210330/Researchers-examine-the-evolutionary-race-between-SARS-CoV-2-and-human-defenses.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cardiovascular risks post-COVID-19 vaccination: Key findings